A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Fezolinetant (Primary)
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Ogeda
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.